Suven Pharmaceuticals Profit & Loss Annual

Trade
BSE: 543064 | NSE: SUVENPHAR | ISIN: INE03QK01018 | Sector: Biotechnology & Drugs
630.25 +0.55 (0.09%)Updated : 24 May 2024
Fiscal Period2023202220212020
Period End DateMar 23Mar 22Mar 21Mar 20
Revenue 1,340.331,320.221,009.72833.79
Total Revenue 1,340.331,320.221,009.72833.79
Costof Revenue Total 568.34550.28415.34319.67
Gross Profit 771.99769.94594.38514.12
Selling/ General/ Admin Expenses Total 196.86179.96142.84128.98
Research Development 85.86103.55110.58-
Depreciation/ Amortization 47.7339.1031.6423.86
Total Operating Expense 821.52779.69600.87472.52
Operating Income 518.81540.53408.84361.27
Interest Inc( Exp) Net- Non- Op Total 375.32514.67546.79424.39
Gain( Loss)on Saleof Assets -0.07-2.010.340.58
Other Net 3.4075.794.120.75
Net Income Before Taxes 559.73667.59467.67404.51
Provisionfor Income Taxes 148.44213.79105.3387.51
Net Income After Taxes 411.29453.80362.34317.00
Net Income Before Extra Items 411.29453.80362.34317.00
Net Income 411.29453.80362.34317.00
Income Availableto Com Excl Extra Ord 411.29453.80362.34317.00
Income Availableto Com Incl Extra Ord 411.29453.80362.34317.00
Diluted Net Income 411.29453.80362.34317.00
Diluted Weighted Average Shares 25.4625.4625.4625.46
Diluted EPS Excluding Extra Ord Items 16.1617.8314.2312.45
DPS- Common Stock Primary Issue 1.002.002.00-
Diluted Normalized EPS 16.1617.8314.2312.45
Total Adjustmentsto Net Income -0.00--
Other Operating Expenses Total ---0.00
*All figures in crores except per share values
Recommended For You
Trending Stocks
1,516.65+24.45(1.64%)
1,389.40+15.45(1.12%)
3,625.95+39.80(1.11%)
2,867.40-35.05 (-1.21%)
1,321.90-15.80 (-1.18%)
HomeMarketsPremiumFor youGet App